IL-23 promotes tumour incidence and growth
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Items 101–200 of 1,000
IL-12 Family Cytokines in Cancer and Immunotherapy
Mirlekar, B., & Pylayeva-Gupta, Y. (2021) · Cancers · doi:10.3390/cancers13020167 · Cited by 295
“, where it was observed that the genetic deletion or blockade of IL-23 in mice led to an increased infiltration of cytotoxic T cells with protective effects against cancer [48].”
BackgroundTransmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells
Mahadevan, N. R., Rodvold, J., Sepulveda, H., Rossi, S., Drew, A. F., & Zanetti, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008942108 · Cited by 294
“We note that the expression of Il23p19, which is increased in human cancer tissues and was found to inhibit cytotoxic T-cell function (34), also inhibits innate NK-mediated antitumor immunity (35), and is associated with the plastic differentiation of CD4 T cells into FoxP3/IL-10–secreting regulatory T cells, which su…”
BackgroundHypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
Marchiq, I., & Pouysségur, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1307-x · Cited by 300
“Other studies have shown that lactate also promoted tumour-associated inflammation by increasing the production of cytokines such as IL-23 and IL-6 [62, 82].”
BackgroundDifferential regulation of interleukin 12 and interleukin 23 production in human dendritic cells
Gerosa, F., Baldani-Guerra, B., Lyakh, L. A., Batoni, G., Esin, S., Winkler-Pickett, R. T., Consolaro, M. R., De Marchi, M., Giachino, D., Robbiano, A., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071450 · Cited by 280
Self-citationMuñoz, M., Heimesaat, M. M., Danker, K., Struck, D., Lohmann, U., Plickert, R., Bereswill, S., Fischer, A., Dunay, I. R., Wolk, K., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090900 · Cited by 277
“Effector mechanisms of IL-23 include the up-regulation of matrixmetalloproteinases (MMPs; Langowski et al., 2006), a large family of endopeptidases that mediate homeostasis of the extracellular matrix.”
BackgroundInnate Lymphoid Cells in Mucosal Immunity
Panda, S. K., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00861 · Cited by 275
“Indeed, the key activator of ILC3s, IL-23, and the ILC3 effector cytokines IL-17 and IL-22 are associated with both experimental and clinical tumorigenesis ( Figure 1 ) (139–142).”
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Habanjar, O., Bingula, R., Decombat, C., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044002 · Cited by 263
Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway
Shime, H., Yabu, M., Akazawa, T., Kodama, K., Matsumoto, M., Seya, T., & Inoue, N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7175 · Cited by 285
“Recently, the Oft group (16) showed that IL-23 but not IL-12 is overexpressed by macrophages and DCs in human and mouse tumor tissues.”
BackgroundMethodInfluentialEmerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Papp, K., Thaçi, D., Reich, K., Riedl, E., Langley, R. G., Krueger, J. G., Gottlieb, A. B., Nakagawa, H., Bowman, E. P., Mehta, A., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13932 · Cited by 276
Generation and regulation of human CD4 + IL-17-producing T cells in ovarian cancer
Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., & Wang, R.-F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710686105 · Cited by 279
“the basis of IL-23 mRNA expression (5).”
BackgroundEmmerich, J., Mumm, J. B., Chan, I. H., LaFace, D., Truong, H., McClanahan, T., Gorman, D. M., & Oft, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0721 · Cited by 270
“Tumor models To generate the PDV6-OVA tumor cell line, parental PDV6 cells (18) were transfected with a plasmid expressing a CMV promoter–driven cytoplasmic form of OVA (cOVA; amino acids 20–145; ref.”
MethodSelf-citationKitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., Takahashi, N., & Taketomi, A. (2017) · Cancer Science · doi:10.1111/cas.13332 · Cited by 278
“(47) This report indicated that IL-12 is important for anticancer immunity through induction of Th1 immunity.”
BackgroundInterleukin-27: Balancing Protective and Pathological Immunity
Hunter, C. A., & Kastelein, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.11.003 · Cited by 273
“Given the contributory role of inflammation to the development of cancer, and in particular the links to the IL23-Th17 cell axis (Langowski et al., 2006), it seems likely that IL-27 would have some impact on the immunological processes that contribute to these events, but there is a paucity of…”
BackgroundSelf-citationMicrobiome, inflammation and colorectal cancer
Chen, J., Pitmon, E., & Wang, K. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.006 · Cited by 265
Tumor Promotion via Injury- and Death-Induced Inflammation
Kuraishy, A., Karin, M., & Grivennikov, S. I. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.006 · Cited by 261
“Whereas IL-12- and IFN-g-driven cytotoxic T cells inhibit initiation and progression of skin cancer, IL-23- and IL-17-mediated responses promote skin tumorigenesis (Langowski et al., 2006).”
BackgroundTargeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Role of IL-17 and Th17 Cells in Liver Diseases
Hammerich, L., Heymann, F., & Tacke, F. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/345803 · Cited by 261
“It has been suggested that IL-17 and IL-23 can act as angiogenic factors, therefore promoting tumor survival [81, 83–85].”
BackgroundThe prevalence of Th17 cells in patients with gastric cancer
Zhang, B., Rong, G., Wei, H., Zhang, M., Bi, J., Ma, L., Xue, X., Wei, G., Liu, X., & Fang, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.060 · Cited by 257
Principles of adoptive T cell cancer therapy
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31446 · Cited by 261
Lymphocytes in cancer development: Polarization towards pro-tumor immunity
Ruffell, B., DeNardo, D. G., Affara, N. I., & Coussens, L. M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.002 · Cited by 253
“Similarly, IL-12 genetic deficiency increases the frequency of chemically induced sarcomas [84] and papillomas [85], while exogenous IL-12 treatment has the opposite effect [86].”
gp130 at the nexus of inflammation, autoimmunity, and cancer
Silver, J. S., & Hunter, C. A. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0410217 · Cited by 254
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 251
“IL-23 and IL-17 are associated with increased tumor incidence (Langowski et al., 2006).”
Self-citationInterleukin-23 engineering improves CAR T cell function in solid tumors
Ma, X., Shou, P., Smith, C., Chen, Y., Du, H., Sun, C., Porterfield Kren, N., Michaud, D., Ahn, S., Vincent, B., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0398-2 · Cited by 253
Cancer and Inflammation: Implications for Pharmacology and Therapeutics
Balkwill, F., & Mantovani, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.312 · Cited by 249
Nam, J.-S., Terabe, M., Kang, M.-J., Chae, H., Voong, N., Yang, Y.-A., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0206 · Cited by 251
“induced skin carcinogenesis, and in transplantable tumors (38).”
BackgroundInflammation and immune surveillance in cancer
Chow, M. T., Möller, A., & Smyth, M. J. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.004 · Cited by 241
“Immune cell types Tumor-promoting Tumor-suppressive Macrophages Immunosuppression (review in [149]); Promotion of angiogenesis, invasiveness and metastasis [150–152] Production of IL-12 (reviewed in [153]) and NO [154] Dendritic cells Immunosuppression [155,156]; vasculogenesis [157] Production of IL-12 and Type 1 IFN…”
BackgroundWakita, D., Sumida, K., Iwakura, Y., Nishikawa, H., Ohkuri, T., Chamoto, K., Kitamura, H., & Nishimura, T. (2010) · European Journal of Immunology · doi:10.1002/eji.200940157 · Cited by 236
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Dual Roles for Immunity in Gastrointestinal Cancers
Ferrone, C., & Dranoff, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9992 · Cited by 241
“important STAT-3 associated cytokine is IL-23, which is expressed at high levels in human colon carcinoma tissues.(35) IL-23 enhances mac-”
BackgroundStat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
Jarnicki, A., Putoczki, T., & Ernst, M. (2010) · Cell Division · doi:10.1186/1747-1028-5-14 · Cited by 240
“The Th17 subset of T-cells secrete large amounts of IL17A, which induces the angiogenic factors VEGF and TGFβ in fibroblasts and endothelial cells [131], and both IL17 and IL23 promote tumourigenesis [132,133].”
BackgroundImmunology of Toxoplasma gondii
Munoz, M., Liesenfeld, O., & Heimesaat, M. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00992.x · Cited by 239
“Matrixmetalloproteinases (MMPs) have been proposed to play an important role in the pathology of IBD (154) and have been show to be induced by IL-23 (155).”
BackgroundInfluentialTreatments for psoriasis and the risk of malignancy
Patel, R. V., Clark, L. N., Lebwohl, M., & Weinberg, J. M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.12.031 · Cited by 235
Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
Shalapour, S., & Karin, M. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.021 · Cited by 228
“Whereas IL-12 has anti-tumorigenic activity in skin cancer, IL-23 is pro-tumorigenic in both skin and colon (Grivennikov et al., 2012; Langowski et al., 2006; Teng et al., 2010).”
BackgroundCroci, D. O., Zacarías Fluck, M. F., Rico, M. J., Matar, P., Rabinovich, G. A., & Scharovsky, O. G. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0343-y · Cited by 226
“tration of CTLs and subsequent immunosurveillance, while IL-23, which shares the p40 subunit with IL-12, promotes tumor-associated inXammatory responses mediated by the matrix metalloproteinase MMP-9 and angiogenic factors, but reduces CTL inWltration [64].”
BackgroundRegulation of interleukin‐12/interleukin‐23 production and the T‐helper 17 response in humans
Lyakh, L., Trinchieri, G., Provezza, L., Carra, G., & Gerosa, F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00700.x · Cited by 227
“Studies using p19 / or p35 / mice in experimental models of autoimmunity (25–27), tumors (33), and inflammatory bowel disease (34–37) have identified IL-23, rather than IL-12, as the major factor responsible for lesions due to chronic inflammation.”
Adoptive immunotherapy of cancer using CD4+ T cells
Muranski, P., & Restifo, N. P. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.004 · Cited by 220
Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 221
Immunotherapy of cancer by IL-12-based cytokine combinations
Weiss, J. M., Subleski, J. J., Wigginton, J. M., & Wiltrout, R. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1705 · Cited by 221
“However, tumor-promoting properties of IL-23 have also been described [123] .”
BackgroundWu, L., Chen, X., Zhao, J., Martin, B., Zepp, J. A., Ko, J. S., Gu, C., Cai, G., Ouyang, W., Sen, G., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150204 · Cited by 221
“IL-23, an upstream cytokine of Th17 cells, is well documented in promoting tumor development by inducing and maintaining an inflammatory microenvironment optimal for tumor progression (Langowski et al., 2006; Grivennikov et al., 2012).”
BackgroundSelf-citationCytokine-Induced Modulation of Colorectal Cancer
Mager, L. F., Wasmer, M.-H., Rau, T. T., & Krebs, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00096 · Cited by 216
“In primary CRC tissue, IL23A and IL12B transcripts are overexpressed, whereas IL12A mRNA is not upregulated (176).”
BackgroundExpression of RORγt Marks a Pathogenic Regulatory T Cell Subset in Human Colon Cancer
Blatner, N. R., Mulcahy, M. F., Dennis, K. L., Scholtens, D., Bentrem, D. J., Phillips, J. D., Ham, S., Sandall, B. P., Khan, M. W., Mahvi, D. M., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004566 · Cited by 211
Self-citationThe molecular epidemiology of lung cancer
Schwartz, A. G., Prysak, G. M., Bock, C. H., & Cote, M. L. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl253 · Cited by 213
Contextual control of skin immunity and inflammation by Corynebacterium
Ridaura, V. K., Bouladoux, N., Claesen, J., Chen, Y. E., Byrd, A. L., Constantinides, M. G., Merrill, E. D., Tamoutounour, S., Fischbach, M. A., & Belkaid, Y. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171079 · Cited by 214
“794 contribute to tumorigenesis and progression to metastatic disease (Langowski et al., 2006; Wang and Karin, 2015).”
BackgroundIntratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., & Becher, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130678 · Cited by 213
“Others have reported a protumorigenic effect of IL-23 (Langowski et al., 2006).”
BackgroundGut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APC Min/+ mice
Li, Y., Kundu, P., Seow, S. W., de Matos, C. T., Aronsson, L., Chin, K. C., Kärre, K., Pettersson, S., & Greicius, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs137 · Cited by 206
Polarized immune responses differentially regulate cancer development
Johansson, M., DeNardo, D. G., & Coussens, L. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00600.x · Cited by 209
“Th17 responses have also been associated with aspects of cancer development (36).”
BackgroundDysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer
Goc, J., Lv, M., Bessman, N. J., Flamar, A.-L., Sahota, S., Suzuki, H., Teng, F., Putzel, G. G., Eberl, G., Withers, D. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.029 · Cited by 212
Regulation and Function of Proinflammatory TH17 Cells
Martinez, G. J., Nurieva, R. I., Yang, X. O., & Dong, C. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.021 · Cited by 203
Regulation of Antitumor Immune Responses by the IL‐12 Family Cytokines, IL‐12, IL‐23, and IL‐27
Xu, M., Mizoguchi, I., Morishima, N., Chiba, Y., Mizuguchi, J., & Yoshimoto, T. (2010) · Journal of Immunology Research · doi:10.1155/2010/832454 · Cited by 203
“In contrast, although exogenously overexpressed IL-23 enhances antitumor immunity via memory T cells, endogenous IL-23 promotes protumor immunity through STAT3 activation by inducing inflammatory responses including IL-17 production.”
Radiation, Inflammation, and Immune Responses in Cancer
Multhoff, G., & Radons, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00058 · Cited by 202
Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice
Robinson-Smith, T. M., Isaacsohn, I., Mercer, C. A., Zhou, M., Van Rooijen, N., Husseinzadeh, N., McFarland-Mancini, M. M., & Drew, A. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4375 · Cited by 199
“This may indicate local suppression of lymphocytes by tumor cells via secreted factors, such as IL-10, IL-23, and HSP10 (30, 31), and the recruitment of immunosuppressive cells (32, 33).”
BackgroundRole of Stat3 in suppressing anti-tumor immunity
Kortylewski, M., & Yu, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.010 · Cited by 196
IL‐23: One cytokine in control of autoimmunity
Croxford, A. L., Mair, F., & Becher, B. (2012) · European Journal of Immunology · doi:10.1002/eji.201242598 · Cited by 193
Li, Y., Patel, S. P., Roszik, J., & Qin, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 195
“Lactate also acts as an important signaling molecule to promote the production of cytokines such as IL-23 and IL-6 contributing to tumor-associated inflammation (104, 109).”
BackgroundChemoprevention of Colorectal Cancer
Katona, B. W., & Weiss, J. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.06.047 · Cited by 195
Transcriptional regulatory networks in Th17 cell differentiation
Zhou, L., & Littman, D. R. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.001 · Cited by 192
“Current Opinion in Immunology 2009, 21:146–152 progression due to the role of their cytokines in inflammation and tissue repair [8].”
BackgroundTargeting the tumor microenvironment: JAK-STAT3 signaling
Bournazou, E., & Bromberg, J. (2013) · JAK-STAT · doi:10.4161/jkst.23828 · Cited by 189
Jinushi, M., Nakazaki, Y., Dougan, M., Carrasco, D. R., Mihm, M., & Dranoff, G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30966 · Cited by 195
“Furthermore, aged GM-CSF/IFN-γ compound deficient mice succumb at high frequency to hematologic and solid malignancies, consistent with a key role for the IL-23/IL-17 axis in inflammation-driven carcinogenesis (38, 39).”
BackgroundLim, C.-A., Yao, F., Wong, J. J.-Y., George, J., Xu, H., Chiu, K. P., Sung, W.-K., Lipovich, L., Vega, V. B., Chen, J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.038 · Cited by 190
Kangsamaksin, T., Chaithongyot, S., Wootthichairangsan, C., Hanchaina, R., Tangshewinsirikul, C., & Svasti, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189628 · Cited by 190
IL-17 Enhances Tumor Development in Carcinogen-Induced Skin Cancer
Wang, L., Yi, T., Zhang, W., Pardoll, D. M., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0775 · Cited by 185
“This model has been widely used to study how an extrinsic chemically induced inflammation initiates epithelial transformation and promotes subsequent papilloma development (22, 23).”
Th17 cells in cancer: help or hindrance?
Wilke, C. M., Kryczek, I., Wei, S., Zhao, E., Wu, K., Wang, G., & Zou, W. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr019 · Cited by 180
IL-17 in obesity and adipogenesis
Ahmed, M., & Gaffen, S. L. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.10.005 · Cited by 185
“The Th17 lineage and IL-17A are now recognized to play detrimental roles in a wide variety of autoimmune and inflammatory conditions, such as IBD, psoriasis, systemic lupus erythematosus (SLE) and rheumatoid arthritis (15-18).”
Song, X., Gao, H., Lin, Y., Yao, Y., Zhu, S., Wang, J., Liu, Y., Yao, X., Meng, G., Shen, N., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.018 · Cited by 185
“The recently discovered T helper 17 (Th17) cells have been found to play a critical role in promoting cancer (Grivennikov et al., 2010; Langowski et al., 2006).”
BackgroundTRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translation
Chmielewski, M., & Abken, H. (2020) · ADVANCES IN CELL AND GENE THERAPY · doi:10.1002/acg2.84 · Cited by 175
Van Overmeire, E., Laoui, D., Keirsse, J., Van Ginderachter, J. A., & Sarukhan, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00127 · Cited by 180
“For example, M1-type TAM produce cytokines (IL-6, IL-23, IL-1β, TNFα) that promote Th17 differentiation and maintain the chronic inflammatory environment (160).”
BackgroundNeutrophils in the tumor microenvironment: trying to heal the wound that cannot heal
Singel, K. L., & Segal, B. H. (2016) · Immunological Reviews · doi:10.1111/imr.12459 · Cited by 181
“Langowski et al.124 showed that IL-23 promoted tumor incidence and growth in mice.”
BackgroundInfluentialCytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut
Mahapatro, M., Erkert, L., & Becker, C. (2021) · Cells · doi:10.3390/cells10010111 · Cited by 177
In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke
Caballero-Garrido, E., Pena-Philippides, J. C., Lordkipanidze, T., Bragin, D., Yang, Y., Erhardt, E. B., & Roitbak, T. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1641-15.2015 · Cited by 182
“…in stroke (Sola et al., 2008; Peng et al., 2010); Bmp4, encoding bone morphogenetic protein, implicated in induction of tube formation and migration of human microvascular endothelial cells (Rothhammer et al., 2007); and the angiogenesis promoting cytokine gene Il23a (Langowski et al., 2006).”
BackgroundMolecular pathways and targets in cancer-related inflammation
Mantovani, A., Garlanda, C., & Allavena, P. (2010) · Annals of Medicine · doi:10.3109/07853890903405753 · Cited by 185
Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases
Chehimi, M., Vidal, H., & Eljaafari, A. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6070068 · Cited by 166
Gordon, K. B., Langley, R. G., Gottlieb, A. B., Papp, K. A., Krueger, G. G., Strober, B. E., Williams, D. A., Gu, Y., & Valdes, J. M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.304 · Cited by 168
“Mice treated with antibodies to IL-12/IL-23 showed enhanced tumor formation when challenged with squamous carcinoma cells (Langowski et al., 2006).”
BackgroundStagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 166
“Using gene expression profiling from over 3000 cases, Lehmann and colleagues recently described six different TNBC subtypes [Lehmann et al. 2011].”
BackgroundMusolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
The Fire Within: Microbes Inflame Tumors
Gagliani, N., Hu, B., Huber, S., Elinav, E., & Flavell, R. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.006 · Cited by 165
“IL-23 is highly expressed in human colon cancer samples compared to adjacent normal tissue (Grivennikov et al., 2012; Langowski et al., 2006).”
BackgroundOhashi, T., Akazawa, T., Aoki, M., Kuze, B., Mizuta, K., Ito, Y., & Inoue, N. (2013) · International Journal of Cancer · doi:10.1002/ijc.28114 · Cited by 164
IL-23 and Th17 cytokines in intestinal homeostasis
Maloy, K. J., & Kullberg, M. C. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.28 · Cited by 166
Tumor-Elicited Inflammation and Colorectal Cancer
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.014 · Cited by 161
NF-κB as a central regulator of macrophage function in tumors
Biswas, S. K., & Lewis, C. E. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310153 · Cited by 161
IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases
Song, X., & Qian, Y. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.07.021 · Cited by 162
IL-12-and IL-23 in health and disease
Croxford, A. L., Kulig, P., & Becher, B. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.017 · Cited by 160
“lacking the IL-23p19 subunit were almost completely resistant to carcinogen-induced tumor formation (7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoyl-phorbol acetate (TPA)) [87].”
BackgroundCracking the cytokine code in psoriasis
Nickoloff, B. J. (2007) · Nature Medicine · doi:10.1038/nm0307-242 · Cited by 163
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis
Teng, M. W. L., Andrews, D. M., McLaughlin, N., von Scheidt, B., Ngiow, S. F., Möller, A., Hill, G. R., Iwakura, Y., Oft, M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003251107 · Cited by 156
“(16) showed that IL-17 mRNA was barely detectable in the skin of DMBA/ TPA-treated IL-23p19–deficient and IL-12p40–deficient mice compared with WT mice, but did not evaluate papilloma formation in IL-17 mice.”
BackgroundInfluentialSelf-citationDendritic Cell-Based Vaccines: Barriers and Opportunities
Cintolo, J. A., Datta, J., Mathew, S. J., & Czerniecki, B. J. (2012) · Future Oncology · doi:10.2217/fon.12.125 · Cited by 152
“While some literature has implied a role of Th17-related cytokines in tumor promotion due to the presence of IL-23 mRNA in various cancers [169] and Th17 cells in the tumor microenvironment and draining lymph nodes of several tumors [170,171], these findings are nonspecific and do not truly indicate whether or”
BackgroundLiu, Z., Yadav, P. K., Xu, X., Su, J., Chen, C., Tang, M., Lin, H., Yu, J., Qian, J., Yang, P., et al. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0810456 · Cited by 180
Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Moss, M. L., & Minond, D. (2017) · Mediators of Inflammation · doi:10.1155/2017/9673537 · Cited by 153
“Growth of tumors is prevented in IL-23 or IL-23R knockout mice, and genetic deletion or antibody-mediated elimination of IL23 increases the activity of cytotoxic T cells in a model of chemically induced carcinogenesis [44].”
BackgroundInterleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Yan, J., Smyth, M. J., & Teng, M. W. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028530 · Cited by 149
“…(TPA)-promoted two-stage skin carcinogenesis, IL-12/23p40-deficient and IL-23-p19-deficient mice displayed significantly decreased numbers of carcinogen-induced papillomas compared to WT mice, whereas the opposite was observed in IL-12p35-deficient mice (Langowski et al. 2006).”
BackgroundResultInfluentialLupardus, P. J., & Garcia, K. C. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.051 · Cited by 151
“Recently, IL-23 has also been shown to possess tumor-promoting proinflammatory activity and IL23 blockade can render tumors susceptible to infiltration by IL-12-induced cytotoxic T cells.(23) These studies have led to considerable interest in the possibility of therapeutic IL-23 blockade for treatment of autoimmune di…”
Mahadevan, N. R., Anufreichik, V., Rodvold, J. J., Chiu, K. T., Sepulveda, H., & Zanetti, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051845 · Cited by 148
Interferon regulatory factor family of transcription factors and regulation of oncogenesis
Takaoka, A., Tamura, T., & Taniguchi, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00720.x · Cited by 172
Toll-like receptors and immune regulation: implications for cancer therapy
Wang, R.-F., Miyahara, Y., & Wang, H. Y. (2008) · Oncogene · doi:10.1038/sj.onc.1210906 · Cited by 163
Iwahashi (2011) · Oncology Reports · doi:10.3892/or.2011.1201 · Cited by 149
Lin, J.-X., & Leonard, W. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041447 · Cited by 145
The Role of Inflammation in Skin Cancer
Maru, G. B., Gandhi, K., Ramchandani, A. G., & Kumar, G. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_17 · Cited by 159
“While IL-12p35-null mice develop papillomas earlier and more frequently than wild-type mice, IL-23p19-null mice, as well as p40null mice, are resistant to DMBA/TPA induction of skin tumorigenesis (Langowski et al. 2006).”
BackgroundChen, W., Lai, Y., Chen, H., Guo, H., Su, I., & Chen, H. H. W. (2013) · Histopathology · doi:10.1111/his.12156 · Cited by 139
Hirata, T., Osuga, Y., Hamasaki, K., Yoshino, O., Ito, M., Hasegawa, A., Takemura, Y., Hirota, Y., Nose, E., Morimoto, C., et al. (2008) · Endocrinology · doi:10.1210/en.2007-0749 · Cited by 143
“Human tumors show increased expression of IL-17A (31), and IL-17A promotes angiogenesis and tumor growth (32).”
BackgroundChan, I. H., JAIN, R. K., Tessmer, M. S., Gorman, D., Mangadu, R., Sathe, M., Vives, F., Moon, C., Penaflor, E., Turner, S. P., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.101 · Cited by 152
“The potential contribution of IL-23 as a tumor-promoting factor is emphasized by the observation that IL-23 expression is elevated in human CRC tumors.(14) Moreover, induction of skin papillomas following application of a chemical carcinogen plus an inflammatory promoter (12-O-tetradecanoylphorbol-13acetate) was inhib…”
BackgroundSelf-citationChallenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment
Jackson, C. M., Ruzevick, J., Phallen, J. A., Belcaid, Z., & Lim, M. K. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/732413 · Cited by 158
“Finally, there is evidence to suggest that the GBM microenvironment may divert CD4+ T cell differentiation away from a tumor-directed cytotoxic Th1mediated response and toward a Th17-mediated chronic inflammatory response [30], which has been shown to be protumorigenic in other cancers [31].”
BackgroundChiu, H., Chen, C., Wu, M., Cheng, Y. ‐., & Tsai, T. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12461 · Cited by 144
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.